The Approach to High Risk Bladder Cancers in the Absence of Bacillus Calmette Guerin: What should Be the Treatment and Follow Up?

Türker, PolatTürkeri, Levent2022-05-112022-05-1120142147-2270https://doi.org/10.4274/UOB.09https://hdl.handle.net/20.500.11776/8510Bacillus Calmette Guerin (BCG), is the optimal bladder-sparing treatment option for patients with high-risk, non-muscle invasive bladder cancer. Recently, the application of BCG has been hindered due to the problem of its availability in Turkey. Alternative treatment options are needed until this problem is solved. In this article, the recommendations about the preferred treatment options and the follow-up, are summarized in the light of the current literature.tr10.4274/UOB.09info:eu-repo/semantics/openAccessBBCGhigh risk non-muscle invasive bladder cancerEMDAthermo-chemotherapyThe Approach to High Risk Bladder Cancers in the Absence of Bacillus Calmette Guerin: What should Be the Treatment and Follow Up?Review Article132103108N/AWOS:000219410600009